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Abstract
Objectives—Gemcitabine is a potent radiosensitizer. When combined with standard
radiotherapy (XRT) the gemcitabine dose must be reduced to about 10% of its conventional dose.
Oxaliplatin and erlotinib also have radiosensitizing properties. In vitro, oxaliplatin and
gemcitabine have demonstrated synergy. We aimed to determine the maximum tolerated dose of
oxaliplatin and gemcitabine with concurrent XRT, then oxaliplatin, gemcitaibine and erlotinib
with XRT in the treatment of locally advanced and low volume metastatic pancreatic or biliary
cancer.
Methods—A modified 3 + 3 dose escalation design was employed testing 4 dose levels of
oxaliplatin and gemcitabine given once weekly for a maximum of 6 weeks with daily XRT in
fractions of 1.8 Gy to a total dose of 50.4 Gy. Dose limiting toxicity (DLT) was defined as any
grade 4 toxicity or grade 3 toxicity resulting in treatment delay greater than one week.
Additionally, dose reduction in two of three patients in a given cohort was counted as a DLT in
dose escalation-deescalation rule in the modified 3 + 3 design.
Results—Eighteen patients were enrolled, all with pancreatic cancer. Grade 4 transaminitis in a
patient in cohort 3 resulted in cohort expansion. Cohort 4, the highest planned dose cohort, had no
DLTs. The recommended phase II dose (RPTD) is oxaliplatin 50 mg/m2/wk with gemcitabine 200
mg/m2/wk and 50.4 Gy XRT The most prevalent grade 3 toxicities were nausea (22%), elevated
transaminases (17%), leucopenia (17%) and hyperglycemia (17%). Median progression free
survival was 7.1 months (95% CI, 4.6–11.1 months) and median overall survival was 10.8 months
(95% CI, 7.1–16.7 months). The addition of erlotinib was poorly tolerated at the first planned dose
level, but full study of the combination was hindered by early closure of the study.
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Conclusions—Weekly oxaliplatin 50 mg/m2/wk combined with gemcitabine 200 mg/m2/wk
and XRT for pancreatic cancer has acceptable toxicity and interesting activity.
Introduction
A significant fraction of patients with pancreatic cancer have unresectable locally advanced
disease at diagnosis with a median overall survival (OS) in the range of 9 to 12 months[1].
Despite assiduous research, there has been relatively little advancement in the treatment of
locally advanced pancreatic cancer. Recently there has been significant debate about the
relative effectiveness of chemoradiotherapy versus chemotherapy alone[2]. However, the
consequences of failure to control local disease should not be underestimated; uncontrolled
primary disease has been associated with pain, nausea, vomiting, weight loss, obstruction
and decreased survival [3].
A number of studies have investigated chemoradiotherapy in locally advanced pancreatic
cancer. Cancer and Leukemia Group B conducted a phase II trial of low-dose twice weekly
gemcitabine (60mg/m2) and concurrent radiation (XRT, 50.4 Gy) with considerable toxicity
and a median OS of 8.2 months.[4] There has been similar toxicity in other phase II trials
using higher doses of gemcitabine administered once or twice weekly with relatively small
radiation fields. As an example, a European phase II study tested weekly gemcitabine (100
mg/m2 as a continuous infusion over 24 hours) plus concurrent XRT (50.4 Gy), followed by
five cycles of standard-dose gemcitabine, in patients with locally advanced pancreatic
cancer. Grade 3/4 toxicity was observed in half the patients, but the median OS was 15.5
months and 25% of patients were alive at two years[5]
Oxaliplatin has synergistic cytotoxicity when combined with gemcitabine in human cancer
cell lines in vitro or in xenografts. [6] Several clinical trials have demonstrated the efficacy
of oxaliplatin and gemcitabine in various solid tumors, including pancreatic cancer, with
response rates ranging from 10 to 30%, but no improvement in OS has been demonstrated
[7–9]. Two recent phase 1 clinical trials in pancreatic cancer demonstrated the feasibility of
combining oxaliplatin and gemcitabine with concurrent XRT encompassing narrower
radiation fields [10, 11].
Our aim was to define the safety and tolerability of gemcitabine and oxaliplatin given on a
once weekly schedule with full doses of XRT for maximum local control, in the treatment of
locally advanced and/or low volume metastatic pancreatic cancer. A second phase of the
study, which added erlotinib to the combination, was initiated but not completed due to
termination of funding; results for the patients enrolled in that substudy are also presented.
Methods
Patients
The study (National Clinical Trials Number, NCT00266097, local IRB# 04-MED-294-
ORC) was performed at two academic centers. Eligible patients had biopsy proven
unresectable locally advanced or metastatic (at the discretion of the treating team) pancreatic
carcinoma, ECOG performance status 0–2, a life expectancy greater than 2 months,
adequate hematologic, renal and hepatic function, and a washout period of at least 3 weeks
after previous anticancer therapy. During the second phase of the study (erlotinib phase),
patients taking strong inducers or inhibitors of CYP3A were required to stop the medication
to enter the study. The human subjects committees at each participating center approved this
study and all patients provided written informed consent prior to participation. All trial
procedures were conducted in accordance with the principles established by the Helsinki
Declaration.
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In the first part of the study, doses of gemcitabine and oxaliplatin were escalated using a
modified 3 + 3 dose escalation design (Table 1). The second portion of the study added
erlotinib (administered daily beginning on day1) p to the doses of gemcitabine and
oxaliplatin that were one level below the recommended phase II dosing determined in the
first part of the study. Gemcitabine was administered over 30 minutes and oxaliplatin was
administered over 2 hours weekly during radiotherapy. Dose-limiting toxicity (DLT) was
defined as any grade 4 toxicity, or grade 3 toxicity causing a delay in treatment for more
than a week. Additionally, a dose level was deemed to be too toxic if dose reductions were
required for two of three patients in a given cohort. This modification of the standard 3 + 3
dose escalation-de-escalation design prevents selection of a recommended phase II dose
(RPTD) with a high rate of dose reductions. A dose level with 6 patients treated was
considered intolerable if two occurrences of DLT were observed, or at least one DLT and
dose reduction in at least 2 patients with the prior level declared the maximum tolerated dose
(MTD). Gemcitabine and oxaliplatin dose reduction was allowed, with 20% dose reduction
for grade 3 and 40% reduction for grade 4 toxicity. All agents were held if radiotherapy was
held for toxicity. Additionally, all therapy was held for weight loss of 15% or more.
Radiotherapy was administered in fractions of 1.8 Gy to a total dose of 50.4 Gy using
conformal planning and a multi-field technique. Gross tumor volume (GTV) was defined as
the tumor as visualized on CT or MRI or as defined by operative findings including the
pancreatic mass and any lymph nodes measuring more than 1.5 cm. Clinical target volume
(CTV) was defined by expanding the GTV by 1 to 1.5 cm in directions for which there is no
anatomic barrier to microscopic spread. An additional margin of at least 1.0 cm was added
to the CTV for set up error and patient movement.
Safety evaluations were made at baseline and at weekly visits and included history and
physical examinations, laboratory panels, and measurements of CA 19-9 at the outset and at
the end of XRT. Response assessment by CT or MRI was done one month after completion
of study therapy according to the Response Evaluation Criteria in Solid Tumors (RECIST
v1.0). Adverse events were scored according to the National Cancer Institute Common
Terminology Criteria of Adverse Events (CTCAE v3.0)
Descriptive analyses were performed for all the demographic and analytic data. Categorical
data were summarized using frequency tables and summary statistics such as mean, median,
standard deviation, and range were obtained for continuous data. Survival was analyzed
using the Kaplan-Meier statistic.
Results
A total of 18 patients were treated on this protocol (Table 2). All had pancreatic cancer. The
median age was 60. Four patients had chemotherapy prior to study treatment. Most of the
tumors were in the head of the pancreas. One patient had low-volume metastatic disease that
had progressed on gemcitabine-based chemotherapy.
Table 3 describes grade 3 and 4 toxicities. One DLT (grade 4 elevated AST without
evidence of cholangitis) occurred in a patient at dose level 3 and a dose reduction occurred
in one patient. This dose level was expanded to 6 patients and no other patients experienced
a DLT or dose reduction. One patient experienced a DLT and one patient a dose reduction at
dose level 4, the highest dose level evaluated. After expansion of this dose level, the
erlotinib study began, as described below.
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Common grade 1 and 2 toxicities were nausea, vomiting, diarrhea, weight loss,
thrombocytopenia and leukopenia. The most commonly encountered grade 3 toxicities were
nausea (22%), elevated transaminases (17%), leucopenia (17%) and hyperglycemia (17%).
Treatment delays and subsequent dose reductions occurred at dose level 1 (n=1), dose level
2 (n=2), dose level 3 (n=2 of 6, one of which was a DLT) and dose level 4. The highest
tested combination was gemcitabine 200 mg/m2 weekly, oxaliplatin 50 mg/m2 weekly and
XRT 50.4 Gy over 5 to 6 weeks, which produced manageable toxicity and represents the
dose we would recommend for further evaluation.
All 18 patients completed XRT and each was evaluable for response assessment. Responses
included one partial response, one complete response, and 14 (78%) with stable disease.
Only 2 patients experienced progression at their first evaluation. Median progression free
survival was 7.1 months (95% CI, 4.6–11.1 months) and median OS was 10.8 months (95%
CI, 7.1–16.7 months).
Five patients were treated in Part 2 of the study, in which erlotinib was added to gemcitabine
and oxaliplatin (Table 1). At dose level 1, two DLTs occurred. One patient was hospitalized
for nausea, vomiting and diarrhea and another missed more than a week of treatment due to
weight loss and cytopenias. This prompted de-escalation to dose level -1. Accrual was slow,
however, and the study was closed early because the sponsors withdrew funding. Grade 3
toxicities in the limited number of patients treated included cytopenias, nausea, vomiting,
diarrhea and anorexia.
Discussion
There is a persistent controversy over how best to treat locally advanced and metastatic
pancreatic cancer and little convincing evidence to recommend any ‘new’ therapy since
gemcitabine was approved in the 1990s. However, a strong rationale remains for studying
new chemoradiotherapy regimens. Localized disease may profoundly affect quality of life
and control of local disease may help palliate some of the most agonizing symptoms of
pancreatic cancer-- pain, obstruction and cachexia. Radiotherapy, using chemosensitizing
agents, may have an important role in the management of local disease. Gemcitabine acts as
a radiosensitizer when combined with standard XRT, however gemcitabine doses must be
reduced by approximately 10 to 30% of conventional doses, delivering suboptimal systemic
drug concentrations[1]. Oxaliplatin also has radiosensitizing properties, and combinations of
oxaliplatin and gemcitabine have demonstrated synergy in various studies. Combining the
two agents in the locally advanced setting may improve systemic effect, and at the same
time provide local control. We were able to demonstrate that full dose XRT can be
integrated safely into this combination regimen. The highest tested combination was
gemcitabine 200 mg/m2 and oxaliplatin 50 mg/m2 weekly with 50.4 Gy XRT over 5 to 6
weeks, which produced manageable toxicity.
Two other recent phase I/II trials have investigated the feasibility of using oxaliplatin and
gemcitabine and concurrent XRT in the treatment of pancreatic cancer. One group of
investigators administered oxalipatin (escalated to 85 mg/m2), full dose gemcitabine and an
attenuated XRT dose. Grade 3 and 4 toxicities included thrombocytopenia, worsening of
performance status, GI bleed, and other GI toxicities[10]. Another group administered two
cycles of gemcitabine and oxaliplatin followed by escalating weekly doses of oxaliplatin (up
to 70 mg/m2), a fixed dose of gemcitabine (300 mg/m2) and radiotherapy to 45 Gy (for a
total of 5 weeks) with acceptable toxicity[11]. Median time to progression was 8 months and
OS was 17 months
In our study, oxaliplatin and gemcitabine were also combined at less than standard doses but
with a conventional dose of radiotherapy. There was no major toxicity at the highest planned
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doses of the two agents. PFS and OS in this study compares favorably to the survival results
found in the Laurent study [11], which was very similar in design. Recent data from a
chemotherapy-first approach in locally advanced pancreatic cancer[12] suggest that perhaps
a strategy of chemotherapy alone followed by chemoradiation for patients who do not
progress systemically is an approach with the best tradeoff between efficacy and
minimization of toxicity. A gemcitabine/oxaliplatin/radiotherapy combination would be
worth exploring within such a trial.
Our experience with erlotinib was limited by trial closure, but was associated with
significant toxicity at the first planned dose level. Others have had experience with erlotinib
plus radiotherapy combinations in pancreatic cancer. Iannitti et al utilized a regimen of
gemcitabine (75 mg/m2 weekly), paclitaxel (40 mg/m2 weekly) and erlotinib, with the
finding that erlotinib MTD was 50 mg daily [13]. Using a lower dose of gemcitabine of 40
mg/m2 twice weekly, Duffy et al. found the MTD of erlotinib to be 100 mg daily with
hematologic toxicities comprising the DLTs. OS in that study was particularly interesting at
18.7 mos [14]. Tempering our enthusiasm for further study, however, is the recent
experience in rectal cancer, where the addition of oxaliplatin to 5-FU based chemoradiation
has produced disappointing results [15].
In summary, gemcitabine (200 mg/m2 weekly) and oxaliplatin (60 mg/m weekly) can be
combined with standard-dose RT (1.8 Gy fractions to 5040 Gy). Lower doses of
chemotherapy are required if erlotinib is added, even at only 50 mg daily. OS results in this
study were promising, although the group was somewhat heterogeneous and the sample size
small, tempering our enthusiasm to recommend this regimen for further study.
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Table 1
Dose escalation Schema (note all patients received RT to 50.4 Gy)
Part 1 Oxaliplatin Gemcitabine
Cohort -1 30mg/m2/wk 60mg/m2/wk
Cohort 1 30mg/m2/wk 100mg/m2/wk
Cohort 2 30mg/m2/wk 200mg/m2/wk
Cohort 3 45mg/m2/wk 200mg/m2/wk
Cohort 4 50mg/m2/wk 200mg/m2/wk
Part 2 Oxaliplatin Gemcitabine Erlotinib
Cohort -1 30 mg/m2/wk 60mg/m2 50mg daily
Cohort 1 45 mg/m2/wk 100mg/m2 50mg daily
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Table 2
Demographic data
Median Age (range), years 59.5 (47–79)
Gender, n (%)
  Female 10 (56)
  Male 8 (44)
Race, n (%)
  White 14 (78)
  Black 4 (22)
Disease site (%)
  Head of pancreas 12 (67)
  Body of pancreas 4 (28)
  Overlapping lesion of pancreas 1 (5)
Prior chemotherapy, n (%)
  Yes 2 (11)
  No 16 (89)
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